Anna N. A. Tosteson
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Anna N. A. Tosteson has a total of 226 co-authors. Here are the top co-authors by number of shared publications:
- Christine M. Gunn
The Dartmouth Institute for Health Policy and Clinical Practice, Geisel School of Medicine at Dartmouth College, Lebanon, USA
76 shared publications - Julie E. Weiss
Dartmouth Cancer Center, Lebanon, New Hampshire
76 shared publications - Heather A. Carlos
Dartmouth Cancer Center, Lebanon, New Hampshire
75 shared publications - Janet L. Peacock
Dartmouth College
75 shared publications - Judy Rees
Department of Epidemiology, Geisel School of Medicine at Dartmouth, Dartmouth Cancer Center, Hanover, NH 03755, USA
75 shared publications - Emma Y. Supattapone
Dartmouth College, Hanover, New Hampshire
50 shared publications
Latest Publications
- Open Access
- 23 October 2026
- Published by JMIR Publications Inc. in JMIR Medical Informatics
- Vol. 14, e95370
Patient-Provider Distance in Medicare Outpatient Oncology Telehealth Versus Office Visits, 2021‐2023: Cross-Sectional Claims Analysis
In a cross-sectional analysis of traditional Medicare Fee-For-Service beneficiaries aged 66 years or older with outpatient oncology-related encounters, we found that telehealth modestly extended patient-provider geographic reach but largely operated within existing office-based catchments and preserved rural-urban distance gradients. Equitable telehealth policy should target patients with high travel burden while supporting digital access, navigation, and cross-jurisdiction continuity.
- 23 October 2026
- Published by JMIR Publications Inc. in JMIR Medical Informatics
- Vol. 14, e95370
Open AccessPatient-Provider Distance in Medicare Outpatient Oncology Telehealth Versus Office Visits, 2021‐2023: Cross-Sectional Claims Analysis
In a cross-sectional analysis of traditional Medicare Fee-For-Service beneficiaries aged 66 years or older with outpatient oncology-related encounters, we found that telehealth modestly extended patient-provider geographic reach but largely operated within existing office-based catchments and preserved rural-urban distance gradients. Equitable telehealth policy should target patients with high travel burden while supporting digital access, navigation, and cross-jurisdiction continuity.
- 29 May 2026
- Published by American Society of Clinical Oncology (ASCO) in JCO Oncology Practice
- p. OP2501048
Patient- and Physician-Identified Considerations for Clinical Implementation of a New Risk-Based Prediction Tool to Guide Surveillance Mammography in Breast Cancer Survivors
PURPOSE: Patient, tumor, and treatment factors can help predict the chance that a woman with a history of breast cancer diagnosis will be diagnosed with a second breast cancer within a year of a negative mammogram. This qualitative study elucidates breast cancer survivor and multispecialty physician perspectives on barriers/facilitators to clinical implementation of a risk-prediction tool to support surveillance decisions. MATERIALS AND METHODS: We enrolled women who completed primary breast cancer treatment and physicians from November 2023 to April 2024. Participants were recruited through Breast Cancer Surveillance Consortium's registries; patients participated in one of four focus groups and physicians participated in individual semistructured interviews. Participants were presented with information about an interval cancer risk prediction tool and were prompted to share perspectives on facilitators and barriers to using such a tool. To identify salient themes, thematic analysis was undertaken by three research team members. RESULTS: Participants included 40 physicians and 23 patients. Three themes emerged: (1) evidence needed for tool acceptance, (2) tool features to facilitate usage, and (3) barriers to tool adoption. Both cancer survivor and physician groups were accepting of risk prediction tool use for surveillance imaging when tool development information was available; they perceived the tool would fit within workflows, and data integrity could be verified. Both groups anticipated structural (time) and technological barriers (magnetic resonance imaging availability) could impede adoption. CONCLUSION: Qualitative findings from focus groups and interviews analyzed thematically suggest implementing a risk prediction tool for surveillance imaging requires evidence transparency, health record integration, data integrity protection, and system supports to promote ease of use in clinical settings while mitigating unintended consequences. All are important to consider during tool development and implementation planning.
- 29 May 2026
- Published by American Society of Clinical Oncology (ASCO) in JCO Oncology Practice
- p. OP2501048
Patient- and Physician-Identified Considerations for Clinical Implementation of a New Risk-Based Prediction Tool to Guide Surveillance Mammography in Breast Cancer Survivors
PURPOSE: Patient, tumor, and treatment factors can help predict the chance that a woman with a history of breast cancer diagnosis will be diagnosed with a second breast cancer within a year of a negative mammogram. This qualitative study elucidates breast cancer survivor and multispecialty physician perspectives on barriers/facilitators to clinical implementation of a risk-prediction tool to support surveillance decisions. MATERIALS AND METHODS: We enrolled women who completed primary breast cancer treatment and physicians from November 2023 to April 2024. Participants were recruited through Breast Cancer Surveillance Consortium's registries; patients participated in one of four focus groups and physicians participated in individual semistructured interviews. Participants were presented with information about an interval cancer risk prediction tool and were prompted to share perspectives on facilitators and barriers to using such a tool. To identify salient themes, thematic analysis was undertaken by three research team members. RESULTS: Participants included 40 physicians and 23 patients. Three themes emerged: (1) evidence needed for tool acceptance, (2) tool features to facilitate usage, and (3) barriers to tool adoption. Both cancer survivor and physician groups were accepting of risk prediction tool use for surveillance imaging when tool development information was available; they perceived the tool would fit within workflows, and data integrity could be verified. Both groups anticipated structural (time) and technological barriers (magnetic resonance imaging availability) could impede adoption. CONCLUSION: Qualitative findings from focus groups and interviews analyzed thematically suggest implementing a risk prediction tool for surveillance imaging requires evidence transparency, health record integration, data integrity protection, and system supports to promote ease of use in clinical settings while mitigating unintended consequences. All are important to consider during tool development and implementation planning.
- 1 April 2026
- Published by American College of Physicians in Annals of Internal Medicine
- Vol. 179 (4) , 486-496
Outcomes of Density-Targeted Supplemental Breast Magnetic Resonance Imaging Screening by Breast Cancer Risk: Long-Term Health and Economic Considerations
Federally mandated breast density notifications motivate consideration of supplemental breast magnetic resonance imaging (MRI). To evaluate supplemental breast MRI strategies. Simulation of women at average to 4 times higher-than-average relative risk (RR) for breast cancer incidence undergoing screening digital breast tomosynthesis (DBT) with or without supplemental MRI. Breast Cancer Surveillance Consortium and literature. Women aged 40 years or older. Lifetime. U.S. federal payer. Screening with DBT with or without breast density-targeted MRI by starting age (40, 45, or 50 years) and interval (annual or biennial). Breast cancer deaths averted, false-positive biopsy recommendations, harm-benefit ratios, and incremental cost-effectiveness ratios (ICERs). Across all starting ages and intervals, DBT averted 7.4 to 10.5 breast cancer deaths per 1000 average-risk women screened and 23.2 to 33.6 per 1000 women with 4 times higher-than-average risk. Across all RR levels, DBT with supplemental MRI for women with extremely dense breasts (DBT+MRId) averted 0.1 to 0.8 additional breast cancer deaths and resulted in 22 to 186 additional false-positive biopsy recommendations. False-positive biopsies per breast cancer death averted for biennial DBT+MRId for women with 2 times higher-than-average risk were similar to those associated with DBT in average-risk women. For all risk groups, biennial DBT+MRId starting at age 50 years was more effective but less cost-effective than DBT starting at age 45 years. The ICERs were sensitive to cancer risk, MRI costs, and false-positive biopsy rates. Subgroups considered risk and breast density only. Supplemental MRI for women aged 40 years or older with extremely dense breasts and higher-than-average risk (RR ≥2.0) had harm-benefit ratios similar to biennial DBT alone and could be cost-effective if MRI costs and false-positive biopsy rates are reduced. National Cancer Institute.
- 1 April 2026
- Published by American College of Physicians in Annals of Internal Medicine
- Vol. 179 (4) , 486-496
Outcomes of Density-Targeted Supplemental Breast Magnetic Resonance Imaging Screening by Breast Cancer Risk: Long-Term Health and Economic Considerations
Federally mandated breast density notifications motivate consideration of supplemental breast magnetic resonance imaging (MRI). To evaluate supplemental breast MRI strategies. Simulation of women at average to 4 times higher-than-average relative risk (RR) for breast cancer incidence undergoing screening digital breast tomosynthesis (DBT) with or without supplemental MRI. Breast Cancer Surveillance Consortium and literature. Women aged 40 years or older. Lifetime. U.S. federal payer. Screening with DBT with or without breast density-targeted MRI by starting age (40, 45, or 50 years) and interval (annual or biennial). Breast cancer deaths averted, false-positive biopsy recommendations, harm-benefit ratios, and incremental cost-effectiveness ratios (ICERs). Across all starting ages and intervals, DBT averted 7.4 to 10.5 breast cancer deaths per 1000 average-risk women screened and 23.2 to 33.6 per 1000 women with 4 times higher-than-average risk. Across all RR levels, DBT with supplemental MRI for women with extremely dense breasts (DBT+MRId) averted 0.1 to 0.8 additional breast cancer deaths and resulted in 22 to 186 additional false-positive biopsy recommendations. False-positive biopsies per breast cancer death averted for biennial DBT+MRId for women with 2 times higher-than-average risk were similar to those associated with DBT in average-risk women. For all risk groups, biennial DBT+MRId starting at age 50 years was more effective but less cost-effective than DBT starting at age 45 years. The ICERs were sensitive to cancer risk, MRI costs, and false-positive biopsy rates. Subgroups considered risk and breast density only. Supplemental MRI for women aged 40 years or older with extremely dense breasts and higher-than-average risk (RR ≥2.0) had harm-benefit ratios similar to biennial DBT alone and could be cost-effective if MRI costs and false-positive biopsy rates are reduced. National Cancer Institute.
- Open Access
- 26 November 2025
- Published by American Association for Cancer Research (AACR)
Supplementary Table S1 from Performance of Statistical and Machine Learning Risk Prediction Models for Surveillance Benefits and Failures in Breast Cancer Survivors
Supplementary Table S1 shows the calibration assessment in a sensitivity analysis on LASSO and Elastic-net by enforcing the adjustment of the matching factor.
- 26 November 2025
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Table S1 from Performance of Statistical and Machine Learning Risk Prediction Models for Surveillance Benefits and Failures in Breast Cancer Survivors
Supplementary Table S1 shows the calibration assessment in a sensitivity analysis on LASSO and Elastic-net by enforcing the adjustment of the matching factor.
- Open Access
- 26 November 2025
- Published by American Association for Cancer Research (AACR)
Supplementary Table S2 from Performance of Statistical and Machine Learning Risk Prediction Models for Surveillance Benefits and Failures in Breast Cancer Survivors
Supplementary Table S2 shows the estimated effect sizes on log-odds scale for regression-based modeling approaches for surveillance failure and benefit averaged across 10 imputed datasets.
- 26 November 2025
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Table S2 from Performance of Statistical and Machine Learning Risk Prediction Models for Surveillance Benefits and Failures in Breast Cancer Survivors
Supplementary Table S2 shows the estimated effect sizes on log-odds scale for regression-based modeling approaches for surveillance failure and benefit averaged across 10 imputed datasets.
- Open Access
- 26 November 2025
- Published by American Association for Cancer Research (AACR)
Supplementary Figure S1 from Performance of Statistical and Machine Learning Risk Prediction Models for Surveillance Benefits and Failures in Breast Cancer Survivors
Supplementary Figure S1 shows frequency of predictor inclusion in regression-based models for surveillance failure and benefit across imputed datasets.
- 26 November 2025
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figure S1 from Performance of Statistical and Machine Learning Risk Prediction Models for Surveillance Benefits and Failures in Breast Cancer Survivors
Supplementary Figure S1 shows frequency of predictor inclusion in regression-based models for surveillance failure and benefit across imputed datasets.
- Open Access
- 26 November 2025
- Published by American Association for Cancer Research (AACR)
Supplementary Figure S3 from Performance of Statistical and Machine Learning Risk Prediction Models for Surveillance Benefits and Failures in Breast Cancer Survivors
Supplementary Figure S3 shows ranking of variable importance plot for random forests and gradient boosting machines for surveillance benefit.
- 26 November 2025
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figure S3 from Performance of Statistical and Machine Learning Risk Prediction Models for Surveillance Benefits and Failures in Breast Cancer Survivors
Supplementary Figure S3 shows ranking of variable importance plot for random forests and gradient boosting machines for surveillance benefit.
- Open Access
- 26 November 2025
- Published by American Association for Cancer Research (AACR)
Supplementary Methods from Performance of Statistical and Machine Learning Risk Prediction Models for Surveillance Benefits and Failures in Breast Cancer Survivors
Supplementary Methods show the detailed information of model fitting using the machine learning approaches in this work.
- 26 November 2025
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Methods from Performance of Statistical and Machine Learning Risk Prediction Models for Surveillance Benefits and Failures in Breast Cancer Survivors
Supplementary Methods show the detailed information of model fitting using the machine learning approaches in this work.
- Open Access
- 26 November 2025
- Published by American Association for Cancer Research (AACR)
Supplementary Figure S2 from Performance of Statistical and Machine Learning Risk Prediction Models for Surveillance Benefits and Failures in Breast Cancer Survivors
Supplementary Figure S2 shows ranking of variable importance for random forests and gradient boosting machines for surveillance failure.
- 26 November 2025
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figure S2 from Performance of Statistical and Machine Learning Risk Prediction Models for Surveillance Benefits and Failures in Breast Cancer Survivors
Supplementary Figure S2 shows ranking of variable importance for random forests and gradient boosting machines for surveillance failure.
- 9 October 2025
- Published by American Society of Clinical Oncology (ASCO) in JCO Oncology Practice
- Vol. 22 (7) , OP2400751
Comparing Trends in Telemedicine Use and Geographic Disparities in Utilization Among Patients With Cancer in the United States
PURPOSE: Studies have shown that rural populations were less likely than urban populations to use telemedicine during and after the COVID-19 pandemic. These trends are not well characterized nationally for patients with cancer. METHODS: This cohort analysis, using 2 years of Medicare fee-for-service claims (2020-2021), identified patients with incident or prevalent lung or colon cancer in 2020. Rurality of patient residence was classified using rural-urban commuting area codes as metropolitan, micropolitan, or small town/rural. We used generalized estimating equations to model outpatient (telemedicine and in-person) visit trends in 2020 and 2021 by rurality, adjusting for local COVID-19 rates, US region, and clinical and demographic factors. RESULTS: We identified 355,868 patients (66% lung, 34% colon). Median age was 76 years (standard deviation [SD], 7). 78% of patients lived in metropolitan areas, 85% were White, and 53% female. 44% had at least one instance of chemotherapy, surgery, or radiation treatment in 2020. In 2020, compared with patients residing in metropolitan areas, small town/rural-residing patients were less likely to use telemedicine (1.28 visits per year [95% CI, 1.27 to 1.29] v 2.34 [95% CI, 2.33 to 2.35] for metropolitan patients), had fewer total outpatient in-person visits (12.37 [95% CI, 12.34 to 12.41] v 13.71 [95% CI, 13.70 to 13.72]), and had more emergency department (ED) visits (0.85 [95% CI, 0.84 to 0.86] v 0.48 [95% CI, 0.48 to 0.48]) while inpatient utilization was similar. Similar trends were seen in 2021 and by cancer type. CONCLUSION: Lower rural telemedicine use continued beyond the pandemic onset. Relatively lower in-person and higher ED use suggests that telemedicine expansion did not improve overall access to care for rural patients with cancer.
- 9 October 2025
- Published by American Society of Clinical Oncology (ASCO) in JCO Oncology Practice
- Vol. 22 (7) , OP2400751
Comparing Trends in Telemedicine Use and Geographic Disparities in Utilization Among Patients With Cancer in the United States
PURPOSE: Studies have shown that rural populations were less likely than urban populations to use telemedicine during and after the COVID-19 pandemic. These trends are not well characterized nationally for patients with cancer. METHODS: This cohort analysis, using 2 years of Medicare fee-for-service claims (2020-2021), identified patients with incident or prevalent lung or colon cancer in 2020. Rurality of patient residence was classified using rural-urban commuting area codes as metropolitan, micropolitan, or small town/rural. We used generalized estimating equations to model outpatient (telemedicine and in-person) visit trends in 2020 and 2021 by rurality, adjusting for local COVID-19 rates, US region, and clinical and demographic factors. RESULTS: We identified 355,868 patients (66% lung, 34% colon). Median age was 76 years (standard deviation [SD], 7). 78% of patients lived in metropolitan areas, 85% were White, and 53% female. 44% had at least one instance of chemotherapy, surgery, or radiation treatment in 2020. In 2020, compared with patients residing in metropolitan areas, small town/rural-residing patients were less likely to use telemedicine (1.28 visits per year [95% CI, 1.27 to 1.29] v 2.34 [95% CI, 2.33 to 2.35] for metropolitan patients), had fewer total outpatient in-person visits (12.37 [95% CI, 12.34 to 12.41] v 13.71 [95% CI, 13.70 to 13.72]), and had more emergency department (ED) visits (0.85 [95% CI, 0.84 to 0.86] v 0.48 [95% CI, 0.48 to 0.48]) while inpatient utilization was similar. Similar trends were seen in 2021 and by cancer type. CONCLUSION: Lower rural telemedicine use continued beyond the pandemic onset. Relatively lower in-person and higher ED use suggests that telemedicine expansion did not improve overall access to care for rural patients with cancer.